Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The newer macrolides. Azithromycin and clarithromycin

J M Zuckerman1, K M Kaye

  • 1Temple University School of Medicine, Philadelphia, Pennsylvania, USA.

Infectious Disease Clinics of North America
|September 1, 1995
PubMed
Summary

Newer macrolides like azithromycin and clarithromycin offer advantages over erythromycin, including better bioavailability and fewer side effects. Their efficacy is comparable for common infections, with new roles in specific conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Kaposi' s sarcoma-associated herpesvirus latency-associated nuclear antigen.

Viral immunology·2002
Same author

Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mediates episome persistence through cis-acting terminal repeat (TR) sequence and specifically binds TR DNA.

Journal of virology·2001
Same author

The newer macrolides: azithromycin and clarithromycin.

Infectious disease clinics of North America·2000
Same author

Once-daily dosing of aminoglycoside antibiotics.

Infectious disease clinics of North America·2000
Same author

FDA regulation of medical software.

Journal of health law·2000
Same author

An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.

Journal of virology·1999

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Azithromycin and clarithromycin are newer macrolide antibiotics, structurally similar to erythromycin.
  • They share similar mechanisms of action with erythromycin but offer distinct pharmacokinetic and pharmacodynamic advantages.

Purpose of the Study:

  • To compare the advantages and clinical efficacy of azithromycin and clarithromycin with erythromycin.
  • To explore novel therapeutic applications for these newer macrolides.

Main Methods:

  • Review of existing literature on macrolide antibiotics.
  • Analysis of clinical trial data comparing erythromycin, azithromycin, and clarithromycin efficacy and safety.
  • Examination of antimicrobial activity and tissue penetration.

Related Experiment Videos

Main Results:

  • Azithromycin and clarithromycin demonstrate improved oral bioavailability, longer half-lives, higher tissue concentrations, and reduced gastrointestinal adverse effects compared to erythromycin.
  • Clinical efficacy for respiratory tract and skin/soft tissue infections is comparable across these macrolides.
  • Azithromycin shows efficacy for Chlamydia trachomatis infections; clarithromycin and azithromycin are used in treating disseminated Mycobacterium avium complex (MAC) infections in HIV patients.

Conclusions:

  • Azithromycin and clarithromycin represent advancements over erythromycin due to improved pharmacokinetic profiles and safety.
  • These newer macrolides exhibit comparable clinical efficacy for established indications and expanding roles in specific infections.
  • Further research is warranted to fully define the optimal therapeutic uses of azithromycin and clarithromycin.